Влияние курсового приема L-орнитин- L-аспартата на фиброз и стеатоз печени у больных ассоциированной с нарушениями метаболизма жировой болезнью печени (неалкогольной жировой болезнью печени), имеющих гипераммониемию
Introduction. Hyperammonaemia develops both in cirrhosis and earlier fibrotic stages during metabolic-associated fatty liver disease (MAFLD). Besides neurotropic, ammonia exerts the hepatotoxic and profibrotic effects. L-ornithine-L-aspartate (LOLA) has been proved effective in treatment for hyperam...
Saved in:
Main Author: | Е. V. Garanina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Gastro LLC
2021-12-01
|
Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
Subjects: | |
Online Access: | https://www.gastro-j.ru/jour/article/view/635 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study)
by: M. V. Mayevskaya, et al.
Published: (2018-08-01) -
Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients
by: D. T. Abdurakhmanov, et al.
Published: (2018-08-01) -
The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program
by: V. T. Ivashkin, et al.
Published: (2018-08-01) -
Procalcitonin and C-reactive protein - early predictors of low colorectal anastomotic leakage
by: Yu. A. Shelygin, et al.
Published: (2018-08-01) -
Modern Approaches to Vaccination of Patients with Chronic Liver Diseases and Inflammatory Bowel Diseases against a Novel Coronavirus Infection
by: A. A. Sheptulin, et al.
Published: (2022-09-01)